Current/ Expected Orderbook/ Pending Orders?

The transcript from Glenmark Pharmaceuticals' Q4 FY '25 earnings call does not explicitly provide detailed figures on the current or expected order book or pending orders. However, there is strong emphasis on upcoming launches and market opportunities: - Multiple filings in the U.S. in Q2 FY'26 including 3 MDI (metered-dose inhaler) filings and 2-3 nasal sprays. - Launch of BeiGene in-licensed assets (tislelizumab and a BTK product) with significant market potential in India ($200 million+ PD-1/PD-L1 market). - Continued growth in India with RYALTRIS expected to cross $100 million in sa

Any current/future new fundraising through debt or equity?

Glenmark Pharmaceuticals currently has net debt of around INR 489 crores as of March 2025. There is no explicit mention of any planned new fundraising through debt or equity in the provided transcript. The company has indicated that post-closing a licensing deal with IGI (Innovative Genomics Institute), IGI will be self-sustaining for at least the next 3-4 years without requiring additional investment from Glenmark. Glenmark expects that the licensing deal will cover IGI's expenditure of about $70 million per year. No specific plans for raising new debt or equity are mentioned; the focus is on

Any current/future capex/capital investment/strategic investment?

Monroe plant: $150 million investment remains, mainly in injectable lines and utilities. Goal is to get the plant operational with good filings expected (Page 17). IGI investment: Approximately $70 million annual investment expected over next 3 years, covering clinical trial costs and R&D. After a licensing deal, IGI is expected to be self-sustaining with no further investments needed from Glenmark (Pages 10, 7, 6). Asset additions in FY '25: Total INR 698 crores added; INR 309 crores in Q4 alone (INR 226 crores tangible, INR 84 crores intangible) (Page 6). Planning to transfer some CMC activi

Future growth expectations in sales/revenue/volumes?

FY '26 revenue growth guidance is 10% to 12%. Strong growth expected in ROW (Rest of World) and Europe, with ROW growing 10+% in FY '25 and expected to accelerate. Significant launches in India planned, including BeiGene launches (tislelizumab and zanubrutinib) in early Q1 FY '26. U.S. launches in H2 FY '26, including Flovent approval expected end of Q2 and nasal spray launch in H2. RYALTRIS sales expected to cross $100 million in FY '26, up from $80 million in FY '25. India business growth expected to strengthen after bottoming out in diabetes; other segments like cardio, derm, and respirator

Future growth expectations in earnings/operating earnings/profits/EPS?

Glenmark Pharmaceuticals is targeting a revenue growth of 10% to 12% for FY '26. EBITDA margin guidance is set between 19% to 20%, driven by new product launches such as RYALTRIS and two major U.S. launches in H2 FY '26. Free cash flow generation is expected to be between INR 300 crores to INR 400 crores, post interest and dividend payments. Margin improvement is supported by operational efficiencies, controlled R&D spend (~6-7% of sales), and resolution of manufacturing plant issues. Innovation entity IGI’s $70 million annual investment is expected to be self-sustaining post a licensing deal,

IN US

Sale is live|00:00:00left today

Glenmark Pharmaceuticals LtdQ1 FY25Pharmaceuticals & Biotechnology

Glenmark Pharmaceuticals Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,214P/E: 24.3Market Cap: ₹65.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→FY '26 revenue growth guidance is 10% to 12%.
→Strong growth expected in ROW (Rest of World) and Europe, with ROW growing 10+% in FY '25 and expected to accelerate.
→Significant launches in India planned, including BeiGene launches (tislelizumab and zanubrutinib) in early Q1 FY '26.
→U.S. launches in H2 FY '26, including Flovent approval expected end of Q2 and nasal spray launch in H2.
→RYALTRIS sales expected to cross $100 million in FY '26, up from $80 million in FY '25.
→India business growth expected to strengthen after bottoming out in diabetes; other segments like cardio, derm, and respiratory growing well.
→IGI innovation spend around $70 million annually for next 3 years, to be self-funded post-licensing deal.
→EBITDA margin guidance of 19% to 20%, supported by new product launches and R&D efficiencies.

Margin guidance

Category 2

→Glenmark Pharmaceuticals is targeting a revenue growth of 10% to 12% for FY '26.
→EBITDA margin guidance is set between 19% to 20%, driven by new product launches such as RYALTRIS and two major U.S. launches in H2 FY '26.
→Free cash flow generation is expected to be between INR 300 crores to INR 400 crores, post interest and dividend payments.
→Margin improvement is supported by operational efficiencies, controlled R&D spend (~6-7% of sales), and resolution of manufacturing plant issues.
→Innovation entity IGI’s $70 million annual investment is expected to be self-sustaining post a licensing deal, which will further improve consolidated margins.
→Market expansion in India, Europe, and Rest of World (ROW) with growth in derm, cardio, respiratory, and oncology pipelines.
→Overall EPS and profit growth expected to benefit from margin expansion and stable revenue growth, with management to provide more granularity in upcoming analyst meets.

3 more insights locked — sign up free to unlock

Fundraise plans

→Glenmark Pharmaceuticals currently has net debt of around INR 489 crores as of March 2025.
→There is no explicit mention of any planned new fundraising through debt or equity in the provided transcript.
→The company has indicated that post-closing a licensing deal with IGI (Innovative Genomics Institute), IGI will be self-sustaining for at least the next 3-4 years without requiring additional investment from Glenmark.
→Glenmark expects that the licensing deal will cover IGI's expenditure of about $70 million per year.
→No specific plans for raising new debt or equity are mentioned; the focus is on operational cash generation guided at INR 300 to 400 crores and funding innovation through licensing deals rather than new fundraising rounds.

Order book

→The transcript from Glenmark Pharmaceuticals' Q4 FY '25 earnings call does not explicitly provide detailed figures on the current or expected order book or pending orders.
→However, there is strong emphasis on upcoming launches and market opportunities:
→ - Multiple filings in the U.S. in Q2 FY'26 including 3 MDI (metered-dose inhaler) filings and 2-3 nasal sprays.
→ - Launch of BeiGene in-licensed assets (tislelizumab and a BTK product) with significant market potential in India ($200 million+ PD-1/PD-L1 market).
→ - Continued growth in India with RYALTRIS expected to cross $100 million in sales for FY '26.
→ - Discussions indicate ongoing advanced talks and expected quick closure on the ISB 2001 licensing deal, projected to be transformational.
→Overall, the company demonstrates a healthy pipeline with multiple launches and licensing deals expected to drive future order flow and revenue growth.

Capex plans

Yes

→Monroe plant: $150 million investment remains, mainly in injectable lines and utilities. Goal is to get the plant operational with good filings expected (Page 17).
→IGI investment: Approximately $70 million annual investment expected over next 3 years, covering clinical trial costs and R&D. After a licensing deal, IGI is expected to be self-sustaining with no further investments needed from Glenmark (Pages 10, 7, 6).
→Asset additions in FY '25: Total INR 698 crores added; INR 309 crores in Q4 alone (INR 226 crores tangible, INR 84 crores intangible) (Page 6).
→Planning to transfer some CMC activities to contract development and manufacturing organizations for cost efficiency (Page 15).
→No large expansions in sales force currently planned, existing workforce to drive growth (Page 14).

How does Glenmark Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Glenmark Pharmaceuticals Ltd

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Glenmark Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio